中文

Hong Kong Stocks · Free Data Page

JUNSHI BIO 01877

JUNSHI BIO: FY2025 revenue CN¥2.50B (+28.20% YoY); net income -CN¥840.9M; 2 alerts, 2 watch items out of 17 risk checks; no TTM dividend.
Close PriceHK$15.69Day +4.46%Market CapHK$16.11BP/E—Negative earningsP/B2.37xROE (FY2025)-14.1%Avg. equity

Prices are closing data as of 2026-11-04, not real-time quotes. HK P/E and P/B multiples come from Eastmoney HK key statistics. Metric definitions: P/E, P/B, ROE.

Want the full AI research report for JUNSHI BIO?

This free page compiles public filings, financial ratios and risk screening. Generate a full research report to add business moat & competition, valuation scenarios, catalysts and bull/bear cases right at this URL.

New users who sign up free and verify their email receive 2 free credits for research reports or professional valuation.

10-Year FinancialsFY2016–2025

Financial statements are reported in CNY, while share price and market cap are quoted in HKD.

Key Multi-Year Facts

  • Revenue moved from CN¥3.8M in FY2016 to CN¥2.50B in FY2025 (9-year CAGR +105.9%).
  • Net income was negative in FY2016, FY2017, FY2018, FY2019, FY2020, FY2021, FY2022, FY2023, FY2024, FY2025.

Latest 5 Fiscal Years

Fiscal Year20212022202320242025
Revenue (CNY B)4.021.451.501.952.50
YoY152.4%-63.9%3.4%29.7%28.2%
Net Income (CNY B)-0.72-2.39-2.28-1.28-0.84
Operating Cash Flow (CNY B)-0.64-1.78-2.01-1.44-0.51
ROE-10.4%-27.3%-27.4%-19.7%-14.1%
Gross Margin68.7%63.8%55.6%74.4%79.1%
Net Margin-17.9%-164.2%-151.9%-65.8%-33.7%
Debt-to-Assets24.6%22.1%35.4%44.9%51.1%
Show all 10 fiscal years
Fiscal Year2016201720182019202020212022202320242025
Revenue (CNY B)0.000.000.000.781.594.021.451.501.952.50
YoY—-69.4%-18.6%82886.0%105.8%152.4%-63.9%3.4%29.7%28.2%
Net Income (CNY B)-0.13-0.32-0.72-0.74-1.67-0.72-2.39-2.28-1.28-0.84
Operating Cash Flow (CNY B)-0.19-0.35-0.51-1.19-1.50-0.64-1.78-2.01-1.44-0.51
ROE-11.6%-28.5%-32.3%-23.6%-37.7%-10.4%-27.3%-27.4%-19.7%-14.1%
Gross Margin73.8%61.1%71.4%88.3%76.6%68.7%63.8%55.6%74.4%79.1%
Net Margin-3487.4%-27948.1%-76703.9%-96.0%-104.4%-17.9%-164.2%-151.9%-65.8%-33.7%
Debt-to-Assets2.0%8.2%22.0%32.4%27.1%24.6%22.1%35.4%44.9%51.1%

Fiscal years follow the period-end calendar year (hover headers for period-end dates). ROE uses average beginning/ending equity. Source: HKEX / Eastmoney financial statements, compiled mechanically without AI. Official filings

Risk ChecklistAs of 2026-11-05

Rules-based screening using HK financial statements and HKEX announcement categories (no AI opinions).

2Alert 2Watch 11Pass 2N/A

Items Flagged for Review

  • Alert

    Interest CoverageSolvency

    Negative (negative EBIT)

    FY2025 (ended 2025-12-31) · What is this?

  • Alert

    Net LossesGoing Concern

    FY2025 (2025-12-31) CN¥-0.84B, FY2024 (2024-12-31) CN¥-1.28B

    FY2025 (ended 2025-12-31)

  • Watch

    High Cash & High DebtSolvency

    cash 23.4% of assets, total debt 26.8% of assets

    Q3 (2026-09-30)

  • Watch

    Profit WarningMaterial Events

An "Alert" or "Watch" item flags a number that merits verification in primary filings, not a sell signal.

Dividends

No dividends paid over the trailing 12 months.

Figures are gross HKD per share before applicable withholding or Stock Connect dividend taxes.

More data: All research reports · Sector leaders · Market hours & holidays.

Compiled mechanically from public filings and market quotes (data as of 2026-11-05). For informational purposes only, not investment advice.